Get the Stockscreener App
75.56
0.29%
-0.22
After Hours:
75.56
Ionis Pharmaceuticals Inc stock is traded at $75.56, with a volume of 1.58M.
It is down -0.29% in the last 24 hours and up +0.98% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$75.78
Open:
$75.71
24h Volume:
1.58M
Relative Volume:
0.76
Market Cap:
$12.49B
Revenue:
$1.06B
Net Income/Loss:
$-326.58M
P/E Ratio:
-35.94
EPS:
-2.1022
Net Cash Flow:
$-977.73M
1W Performance:
+1.79%
1M Performance:
+0.98%
6M Performance:
-0.70%
1Y Performance:
+127.18%
1-Day Range:
$75.00
$76.80
1-Week Range:
$71.93
$76.80
52-Week Range:
$32.00
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
75.56 | 12.52B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts - inkl
Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook Highlights 33.56% Potential Upside - DirectorsTalk Interviews
Understanding Momentum Shifts in (IONS) - Stock Traders Daily
IONS Q1 earnings & sales beat, stock rises on raised '26 view - MSN
Ionis Pharmaceuticals’ SWOT analysis: stock gains momentum on FDA approval - Investing.com India
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Ionis Pharmaceuticals Inc : Citigroup Initiat - Moomoo
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st
IONS Initiated Coverage by Citigroup -- Price Target Set at $115 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Bullish Target from Citi A - GuruFocus
J.P. Morgan Initiates Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $115 - Moomoo
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Citigroup initiates coverage of Ionis Pharmaceuticals (IONS) with buy recommendation - MSN
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Biotech Powerhouse with 35.77% Upside Potential - DirectorsTalk Interviews
Biogen posts mid-stage trial data for Alzheimer’s candidate developed with Ionis - MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares - Investing.com
Ionis (NASDAQ: IONS) CEO sells 4,536 shares after option exercise - Stock Titan
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $105 to $115 - Moomoo
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
T. Rowe Price holds 6.16M IONS shares (NYSE: IONS) — 3.7% stake - Stock Titan
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Ionis validates ABL Bio’s Grabody-B to deliver RNA drugs to brainCHOSUNBIZ - Chosunbiz
Ionis Pharmaceuticals, Inc.Common Stock (NQ: IONS - FinancialContent
Biogen has seen enough — despite no dose response — to advance tau-directed therapy - FirstWord Pharma
Capital World Investors holds 12.8% of Ionis (NASDAQ: IONS) - Stock Titan
Biogen AD drug shows tau, cognition benefit, despite trial miss - BioWorld News
Number of shareholders of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Biogen plans registrational study for Alzheimer’s drug diranersen - Investing.com UK
Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen - marketscreener.com
Biogen plans registrational study for Alzheimer’s drug diranersen By Investing.com - Investing.com Canada
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - ChartMill
Pinnacle Associates Ltd. Reduces Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Moves - Yahoo Finance
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Avoiding Lag: Real-Time Signals in (IONS) Movement - Stock Traders Daily
Brett Monia sells 160,773 IONS shares (IONS) via Form 144 - Stock Titan
Oppenheimer Maintains an “Outperform Rating” on Pharmaceuticals, Inc. (IONS) - Yahoo Finance
Amyotrophic Lateral Sclerosis (ALS) Market to Reach USD 1.22 - openPR.com
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):